Tecos study funding

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 ...

★ ★ ★ ★ ★

BackgroundData are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and ...

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 ...

Primary Endpoint met for Trial Evaluating Cardiovascular ...

★ ★ ★ ☆ ☆

TECOS enrolled 14,724 participants from 38 countries between December 2008 and July 2012 with a median follow-up of three years. See TECOS-study.org. Funding was provided by Merck, known as MSD outside of the United States and Canada, who

Primary Endpoint met for Trial Evaluating Cardiovascular ...

TECOS Sitagliptin CV Safety Diabetes Expert Blog Vivian ...

★ ★ ☆ ☆ ☆

expert commentary Vivian Fonseca, MD, on Results of TECOS, the Cardiovascular Safety Study of the DPP-4 Inhibitor, Sitagliptin TECOS was a randomized, placebo-controlled trial that was initiated before the FDA instituted requirements for cardiovascular outcome trials with diabetes drugs.

TECOS Sitagliptin CV Safety Diabetes Expert Blog Vivian ...

Sitagliptin and risk of fractures in type 2 diabetes ...

★ ★ ★ ★ ☆

We used data from 14 671 participants in the TECOS study who were randomized double‐blind to sitagliptin (n = 7332) or placebo (n = 7339). Cumulative fracture incidence rates were calculated and their association with study treatment assignment was examined using …

Sitagliptin and risk of fractures in type 2 diabetes ...

Effect of race on the glycaemic response to sitagliptin ...

★ ★ ★ ★ ☆

for the TECOS Study Group. Search for more papers by this author. First published: ... Cited by: 2. Funding information Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey. [Correction added on 13 March 2018, after first online publication: ‘Oriental Asian’ has been ...

Effect of race on the glycaemic response to sitagliptin ...

Pancreatic Safety of Sitagliptin in the TECOS Study ...

★ ★ ★ ★ ☆

2/1/2017 · The TECOS study demonstrated, on a background of usual care, that there was no difference between treatment groups in the rates of major cardiovascular events, heart failure, or death from any cause. This study examined whether there was an association between the use of sitagliptin and pancreatic disease.

Pancreatic Safety of Sitagliptin in the TECOS Study ...

Analyses of Results From Cardiovascular Safety Trials With ...

★ ★ ☆ ☆ ☆

8/1/2016 · The U.S. Food and Drug Administration requires that the cardiovascular (CV) safety of all new drugs for diabetes be demonstrated through pooled analyses of phase III studies or specifically designed trials. This requirement prompted several placebo-controlled, noninferiority CV safety trials in high-risk patients; to date, all completed trials showed that dipeptidyl peptidase (DPP)-4 ...

Analyses of Results From Cardiovascular Safety Trials With ...

Rationale, design, and organization of a randomized ...

★ ★ ★ ★ ☆

Trial organization and funding. TECOS is sponsored by Merck Sharp & Dohme Corp and managed collaboratively by the DCRI (Durham, NC) and the DTU (Oxford, UK). Prior to database lock, the sponsor will retain the randomization codes but all data (except for key safety data) will be held by the DCRI and DTU and analyzed only in a blinded fashion.

Rationale, design, and organization of a randomized ...

Primary Endpoint met for Trial Evaluating Cardiovascular ...

★ ★ ★ ★ ☆

Primary Endpoint met for Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) TECOS Results presented at the 75th Scientific Sessions of the American Diabetes Association convention ...

Primary Endpoint met for Trial Evaluating Cardiovascular ...

Cardiovascular safety of ... - PubMed Central (PMC)

★ ★ ★ ★ ★

To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin comparators. A post hoc assessment of cardiovascular safety in 14,611 patients was performed by pooling data from 25 double-blind studies, which ...

Cardiovascular safety of ... - PubMed Central (PMC)

New TECOS Analysis Adds Heart Failure Data For Sitagliptin

★ ★ ★ ★ ★

Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history of heart failure - a new analysis of the TECOS (Trial Evaluating Cardiovascular Outcomes with ...

New TECOS Analysis Adds Heart Failure Data For Sitagliptin

Saxagliptin and Cardiovascular Outcomes in Patients with ...

★ ★ ★ ★ ★

Study Oversight. SAVOR-TIMI 53 was a multicenter, randomized, double-blind, placebo-controlled, phase 4 trial. We conducted the trial at 788 sites in 26 countries (see the Supplementary Appendix ...

Saxagliptin and Cardiovascular Outcomes in Patients with ...

Primary Endpoint met for Trial Evaluating Cardiovascular ...

★ ★ ★ ★ ☆

6/8/2015 · See TECOS-study.org *Funding was provided by Merck & Co., Inc., Kenilworth, NJ, USA, (known as MSD outside the United States and Canada) who market sitagliptin (JANUVIA®).

Primary Endpoint met for Trial Evaluating Cardiovascular ...

Silvio Inzucchi No HF With Sitagliptin TECOS Type 2 ...

★ ★ ★ ★ ★

The main interest in TECOS was about its heart failure findings. Less than 2 years before, the SAVOR-TIMI 53 study 2 reported similar neutrality on major adverse cardiovascular events (MACE) for another member of this class, saxagliptin. However, a 27% relative increase in the risk for heart failure hospitalization was found in the active ...

Silvio Inzucchi No HF With Sitagliptin TECOS Type 2 ...

PERS&O (PERsistent Sitagliptin treatment & Outcomes ...

★ ★ ★ ★ ☆

7/1/2016 · Objectives The UK Prospective Diabetes Study (UKPDS) Risk Engine (RE) provides the best risk estimates available for people with type 2 diabetes (T2D), so it was applied to patients on persistent sitagliptin treatment. Design A ‘real-world’ retrospective, observational, single-center study. Setting The study was performed in a general hospital in Northern Italy in order: (1) to validate ...

PERS&O (PERsistent Sitagliptin treatment & Outcomes ...

Safety of sitagliptin in patients with type 2 diabetes and ...

★ ★ ★ ☆ ☆

To characterize the incidence of diabetes-associated complications and assess the safety of sitagliptin in participants with chronic kidney disease (CKD) in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).For participants with baseline eGFR measurements (n = 14 528), baseline characteristics and safety outcomes were compared for the CKD cohort (eGFR

Safety of sitagliptin in patients with type 2 diabetes and ...

Impact of glycemic control with sitagliptin on the 2-year ...

★ ★ ☆ ☆ ☆

While the TECOS study and EXAMINE study failed to confirm improvement of the cardiovascular outcomes by DPP-4 inhibitor treatment , ... Funding. This study is supported by a research grant from the Clinical Research Promotion Foundation (No. 1026). The funding body had no role in study design, data collection and analysis, decision to publish ...

Impact of glycemic control with sitagliptin on the 2-year ...

Pancreatic Safety of Sitagliptin in the TECOS Study ...

★ ★ ☆ ☆ ☆

Research design and methods: In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a cardiovascular safety study of sitagliptin, all suspected cases of acute pancreatitis and ...

Pancreatic Safety of Sitagliptin in the TECOS Study ...

Primary Endpoint met for Trial Evaluating Cardiovascular ...

★ ★ ★ ☆ ☆

Primary Endpoint met for Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) TECOS Results presented at the 75th Scientific Sessions of the American Diabetes Association convention, Boston, USA. Oxford University and Duke Clinical Research Institute News Release.

Primary Endpoint met for Trial Evaluating Cardiovascular ...

Rationale and design of study of dapagliflozin versus ...

★ ★ ★ ★ ☆

6/12/2018 · Study design. The DIVERSITY-CVR study is an ongoing, prospective, randomized open-label, blinded-endpoint study, registered on the University Hospital Medical Information Network Clinical Trial Registry (UMIN000028014), a non-profit organization in Japan that meets the requirements of the International Committee of Medical Journal Editors (ICMJE).

Rationale and design of study of dapagliflozin versus ...

American Diabetes Association Release: Primary Endpoint ...

★ ★ ★ ☆ ☆

TECOS was designed, run, and analyzed independently by DTU and DCRI, in an academic collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, (known as MSD outside the United States and Canada), who sponsored and funded the study. The TECOS results will be published online in the New England Journal of Medicine on Monday 8 th June 2015.

American Diabetes Association Release: Primary Endpoint ...
National-childrens-study-jam-as.html,National-medical-series-for-independent-study-pdf.html,Nato-ccms-pilot-study-level.html,Nature-study-blog.html,Nazarene-youth-bible-study.html